SpringWorks Therapeutics (NASDAQ:SWTX) Given Consensus Rating of “Hold” by Analysts

SpringWorks Therapeutics (NASDAQ:SWTX) has earned an average rating of “Hold” from the eight ratings firms that are covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $52.57.

Several brokerages have recently issued reports on SWTX. HC Wainwright reissued a “neutral” rating and set a $47.00 price target (down previously from $74.00) on shares of SpringWorks Therapeutics in a report on Wednesday, April 30th. Barclays restated an “equal weight” rating and issued a $47.00 target price (down previously from $63.00) on shares of SpringWorks Therapeutics in a research report on Monday, April 28th. Wedbush restated a “neutral” rating and issued a $47.00 price target (down previously from $81.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. Guggenheim reaffirmed a “neutral” rating and set a $47.00 price target on shares of SpringWorks Therapeutics in a report on Monday, May 12th. Finally, TD Cowen reiterated a “hold” rating and set a $47.00 price objective (down from $66.00) on shares of SpringWorks Therapeutics in a research report on Tuesday, April 29th.

SpringWorks Therapeutics Trading Up 0.4%

Shares of SpringWorks Therapeutics stock opened at $46.96 on Tuesday. The business’s 50 day simple moving average is $45.13 and its 200-day simple moving average is $43.98. The stock has a market capitalization of $3.54 billion, a price-to-earnings ratio of -13.77 and a beta of 0.70. SpringWorks Therapeutics has a twelve month low of $28.21 and a twelve month high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its quarterly earnings data on Friday, May 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.30). The company had revenue of $49.09 million for the quarter, compared to analyst estimates of $64.19 million. SpringWorks Therapeutics had a negative net margin of 115.60% and a negative return on equity of 51.10%. Sell-side analysts predict that SpringWorks Therapeutics will post -2.05 earnings per share for the current year.

Hedge Funds Weigh In On SpringWorks Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Huntington National Bank raised its position in shares of SpringWorks Therapeutics by 38.2% during the 4th quarter. Huntington National Bank now owns 694 shares of the company’s stock worth $25,000 after buying an additional 192 shares in the last quarter. AlphaQuest LLC boosted its holdings in shares of SpringWorks Therapeutics by 70.2% in the fourth quarter. AlphaQuest LLC now owns 1,004 shares of the company’s stock valued at $36,000 after acquiring an additional 414 shares in the last quarter. Twin Tree Management LP acquired a new position in shares of SpringWorks Therapeutics during the first quarter valued at approximately $37,000. Venturi Wealth Management LLC bought a new stake in SpringWorks Therapeutics during the fourth quarter worth approximately $45,000. Finally, State of Wyoming raised its holdings in SpringWorks Therapeutics by 39.5% during the fourth quarter. State of Wyoming now owns 1,530 shares of the company’s stock worth $55,000 after purchasing an additional 433 shares in the last quarter.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.